Comparative Pharmacology
Head-to-head clinical analysis: BRIXADI versus BUPRENORPHINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIXADI versus BUPRENORPHINE.
BRIXADI vs BUPRENORPHINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.
None Documented
Clinical Note
moderateBuprenorphine + Torasemide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide."
Clinical Note
moderateBuprenorphine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid."
Clinical Note
moderateBuprenorphine + Furosemide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide."
Clinical Note
moderateNone Documented
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Terminal elimination half-life is 24-60 hours (mean ~37 hours) due to enterohepatic recirculation and slow dissociation from mu-opioid receptors. Clinically, this allows for every-other-day or thrice-weekly dosing in maintenance therapy.
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Buprenorphine is primarily eliminated via biliary excretion of its metabolites, with approximately 70% of the dose recovered in feces as unchanged drug and metabolites. Renal elimination accounts for about 10-30%, primarily as metabolites.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist
Buprenorphine + Bumetanide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide."